Medications for Pulmonary Arterial Hypertension
31 results
Adcirca (tadalafil)
(Tadalafil)United Therapeutics Corporation
Usage: ADCIRCA® is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability, primarily in patients with NYHA Functional Class II-III symptoms, including idiopathic, heritable PAH, and PAH associated with connective tissue diseases.
Adempas (riociguat)
(riociguat)Bayer HealthCare Pharmaceuticals Inc.
Usage: Adempas is indicated for adult patients with chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH, to improve exercise capacity. It also treats pulmonary arterial hypertension (PAH) to enhance exercise capacity, improve functional class, and delay clinical worsening, either alone or with other therapies.
Alyq (tadalafil)
(Tadalafil)AvKARE
Usage: Tadalafil is indicated for treating pulmonary arterial hypertension (PAH) (WHO Group 1) to enhance exercise ability, primarily in patients with NYHA Functional Class II-III symptoms, including those with idiopathic, heritable PAH, or PAH linked to connective tissue diseases.
Alyq (tadalafil)
(Tadalafil)Teva Pharmaceuticals Inc
Usage: ALYQ® (tadalafil tablets) is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in patients, particularly those with NYHA Functional Class II-III symptoms, including idiopathic, heritable PAH, and PAH tied to connective tissue diseases.
Ambrisentan (ambrisentan)
(ambrisentan)Sun Pharmaceutical Industries, Inc.
Usage: Ambrisentan is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise capacity and delay clinical worsening, primarily in patients with WHO Functional Class II–III symptoms and idiopathic, heritable, or connective tissue disease-associated PAH.
Ambrisentan (ambrisentan)
(Ambrisentan)Exelan Pharmaceuticals, Inc.
Usage: Ambrisentan tablets are indicated for treating pulmonary arterial hypertension (PAH) to improve exercise ability and delay clinical worsening, primarily in patients with WHO Functional Class II–III symptoms due to idiopathic, heritable PAH, or PAH associated with connective tissue diseases.
Bosentan (bosentan)
(Bosentan)Amneal Pharmaceuticals LLC
Usage: Bosentan tablets are indicated for treating pulmonary arterial hypertension (PAH) in adults. They improve exercise ability and reduce clinical worsening in patients with WHO Functional Class II-IV symptoms due to idiopathic or heritable PAH, connective tissue diseases, or congenital heart disease with left-to-right shunts.
Bosentan (bosentan)
(Bosentan)Zydus Pharmaceuticals USA Inc.
Usage: Bosentan tablets are indicated for treating pulmonary arterial hypertension (PAH) in adults. They improve exercise ability and reduce clinical worsening, particularly in patients with WHO Functional Class II-IV symptoms related to idiopathic or heritable PAH, connective tissue diseases, and congenital heart disease with left-to-right shunts.
Epoprostenol (epoprostenol)
(EPOPROSTENOL)Mylan Institutional LLC
Usage: Epoprostenol for injection is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise capacity, primarily in patients with NYHA Functional Class III-IV symptoms, including those with idiopathic, heritable PAH, or PAH associated with connective tissue diseases.
Letairis (ambrisentan)
(AMBRISENTAN)Gilead Sciences Inc
Usage: Letairis is indicated for treating pulmonary arterial hypertension (PAH) in adults to improve exercise ability and delay clinical worsening. It can be used alone or in combination with tadalafil to reduce disease progression risks and improve exercise capacity, primarily for patients with WHO Functional Class II–III symptoms.